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Animals. Germ-free (GF) C57Bl/6J mice were generated via caesarian section and 54 
microbiologically-sterile animals were cross-fostered by GF Swiss-Webster dams at the California 55 
Institute of Technology. GF animals were housed in open-top caging within flexible film isolators 56 
(Class Biologically Clean; Madison, WI) and maintained microbiologically sterile, confirmed via 16S 57 
rRNA PCR from fecal-derived DNA and culture of fecal pellets on Brucella blood agar or tryptic soy 58 
blood agar (Teknova; Hollister CA) under anaerobic and aerobic conditions, respectively. The same 59 
mice as the GF were grown under non-GF conditions. Conventionally-colonized specific pathogen 60 
free (SPF) mice (C57Bl/6J) were housed in autoclaved, ventilated, microisolator caging. All animals 61 
received autoclaved food (LabDiet Laboratory Autoclavable Diet 5010; St Louis, MO) and water ad 62 
libitum, were maintained on the same 12-hour light-dark cycle and housed in the same room of the 63 
facility. All animal husbandry and experiments for this component were approved by the California 64 
Institute of Technology’s Institutional Animal Care and Use Committee (IACUC). All animal 65 
dissections and sample collection for the GF and SPF mouse aspect of the study were carried out at 66 
University of California at San Diego under IACUC approval, protocol S00227M. For MRI imaging, a 67 
female, C57Bl/6 mouse, 8 weeks of age, was obtained from Jackson Laboratory and housed with 68 
food and water ad libitum. For metabolome and microbiome studies, four germ-free (GF) and four 69 
specific-pathogen-free (SPF) female 8-week-old C57Bl/6J mice were acquired from the California 70 
Institute of Technology’s vivarium. Samples of the food the animals were provided were also collected 71 
and analyzed (GF were fed LabDiet 5010 and SPF were fed LabDiet 5053, LabDiet, St. Louis, MO).  72 
An additional 24 male ApoE knockout mice in the C57BL/6J background raised for use in a 73 
study of hypoxia on the murine microbiome according to the methods of Tripathi et al. 20181 were also 74 
analyzed in this study for the effects of high-fat-diet and feeding 13C-Phe on the new bile acids. The 75 
fecal samples collected, and the data presented here were not published in that study and approved 76 
under IACUC S05534. The source data from this murine experiment is available online. 77 
 78 
Human Sample Collection: Fecal samples were collected from two separate pediatric cystic 79 
fibrosis patient cohorts for detection of novel bile acids. One sample set was collected from patients at 80 
the Rady’s Children’s Hospital in San Diego, CA using dual fecal swabs according to the procedure 81 
outlined in the American Gut Project2 under IRB approval #160034. The second collection was done 82 
on CF patients with pancreatic sufficiency, without pancreatic sufficiency and healthy controls at Yale 83 
New Haven Hospital (New Haven, CT) under IRB approval #1206010476 according to the procedure 84 
outlined in3. Two separate IBD cohorts were also analyzed for the presence of the novel bile acids. 85 
The first for detection through GNPS data searching according to the American Gut Project fecal 86 
collection protocols and the second for searching a completely different patient cohort with different 87 
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collection methods and mass spectrometry analysis from the human microbiome project 2 (HMP2) 88 
according to the methods of4. The UCSD stool sample collections from patients with IBD were 89 
collected as part of the UCSD IBD Biobank under IRB #131487. Human infant fecal samples were 90 
collected at the University of Michigan under IRB #103575. 91 
 92 
3D Model Generation:  A female, C57Bl/6J mouse, 8 weeks of age, was euthanized using 93 
carbon dioxide inhalation and then immediately brought to the UCSD Center for Functional MRI. The 94 
MRI images were acquired on a Bruker 7T/20 MRI scanner using a quadrature birdcage 95 
transceiver.  A 3D FLASH protocol with TE/TR=6 ms/15 ms and matrix size 128x64x156 was used, 96 
prescribing a field of view to match the body size. The dicom files from the mouse MRI were imported 97 
into the Invesalius software5. In Invesalius, the dicom files were visualized as stacked images through 98 
the axial, sagittal and coronal slices. Organs of interest were then traced in each slice according to 99 
their best visualization in the different viewpoints. The tracing was done using ‘create new mask’ 100 
feature in Invesalius using the manual edition mode. The brush feature was used to trace the outline 101 
of each organ of interest in the appropriate slice, stack by stack, until the entire organ was outlined 102 
through all slices in each orientation such that its outline was smoothed and did not bleed into other 103 
organs. Numerous iterations of this process led to the mapping of each organ through the MRI 104 
stacked images. The ‘Configure 3D surface’ feature was then used to translate the 2D stack tracings 105 
into a 3D image of each organ. This was completed for all organs sampled except for blood, fecal and 106 
skin samples, successively, until an entire 3D-model of all organs of interest to this study was built. 107 
Blender (https://www.blender.org/) was used to smooth the model and color each organ differently, 108 
enabling better visualization of the different organs and organ systems. Blood and skin samples were 109 
not mapped onto the model and a representative fecal sample was added after MRI modeling using 110 
Invesalius to allow mapping to a theoretical fecal sample. 111 
  112 
Sample Collection. Mice were euthanized via carbon dioxide asphyxiation. Prior to 113 
dissection, external sites including the skin (left and right flank), ears, mouth and feet were sampled 114 
using a cotton swab with vigorous contact for 5 seconds. Blood was collected via cardiac puncture 115 
using a 22-gauge needle and 1 ml syringe. Mice were then sterilely dissected under open flame using 116 
straight scissors and fine forceps that were cleaned with 70% ethanol (v/v) between handling of each 117 
organ. The following organs were dissected: Adrenal gland, bladder, brain, cecum, cervix, colon, 118 
duodenum, esophagus, foot, gall bladder, heart, ileum, jejunum, kidney, liver, lung, ovaries, spleen, 119 
stomach, thymus, trachea, uterus and vagina. Additional samples were collected using swabs 120 
including skin, ear, foot, and mouth. The sample collection order is shown in table S1. Sections of 121 
each organ were made using sterile razor blades, with the number of sections listed in table S1. The 122 
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liver and lung were sectioned into their corresponding lobes (Liver: right and left median lobes, right 123 
and left lobes and caudate lobe; Lung: superior lobe, middle lobe, inferior lobe, post-caval lobe and 124 
left lung lobe). The heart was sectioned into left and right ventricle and left and right atrium. Each 125 
kidney was sub-sectioned by targeting the outer cortex and inner medulla. The uterus was 126 
subsampled by collecting each left and right uterine horn and oviduct and a single sample of the 127 
uterine fundus. The brain was subsampled by collecting the left and right cerebellum and cerebrum. 128 
The GI samples were sectioned into 6 equal length pieces based on the full length of each GI section 129 
(including 6 sections of the cecum). Margins of the duodenum and jejunum were determined at the 130 
site of the suspensory muscle of the duodenum. The junction of the jejunum and ileum was estimated 131 
as 6 cm proximal to the cecum based on previously reported lengths6. The GI samples were not 132 
cleaned or flushed prior to sample collection. The spleen (4 sections), pancreas (3 sections), adrenal 133 
gland (2 sections), and vagina (2 sections) were also sectioned into equal length pieces according to 134 
size (Table S1). It took approximately 45 minutes to fully dissect each mouse immediately after 135 
euthanasia. Four stool samples were also collected from each group of mice from the bedding of the 136 
sterile shipping containers immediately after arrival in the UCSD analysis laboratory. With such 137 
collection method it is not known which mouse produced which stool sample. Food samples fed to 138 
both GF and SPF mice were also collected and analyzed. Sample collection for the additional 139 
published murine studies were completed according to1,7. In addition, fecal samples were collected 140 
from mice fed a high-fat diet starting at 10 weeks and compared to animals fed the control normal 141 
chow diet according to the methods of1. The data from1 was not published as part of that manuscript. 142 
 143 
Sample Processing: All samples were contained in 2 ml sterile Eppendorf® Biopur® Safe-144 
Lock tubes, wet tissue mass recorded, and then frozen at -80°C until metabolite and DNA extraction. 145 
For the swab samples, the wooden end of the swab was cut off with scissors, added to a 146 
microcentrifuge tube and 1 ml of PBS was added. After thawing, all of the non-swab samples were 147 
diluted in a 1:10 mass:volume in sterile phosphate buffered saline. A Qiagen (Qiagen Inc., Valencia, 148 
CA) 5 mm stainless steel bead was added to each tube and the samples were homogenized in a 149 
Qiagen TissueLyzer II homogenizer at a frequency of 20/s for 5 min. After homogenization two 150 
aliquots of 50 μl of the homogenate or PBS/swab mix was added to separate 96-well deep well plates, 151 
one for metabolite extraction and one for DNA extraction. Metabolites were extracted from the 152 
samples in the 96-well deep well plate by adding 200 μl of LC-MS grade 70% methanol in LC-MS 153 
grade water and vortexing each plate for 5 seconds. Samples were left to extract overnight at 4°C and 154 
then spun down to pellet debris in a 96-well plate Sorvall® Legend centrifuge at 2500 rpm for 1 155 
minute. DNA was extracted from the homogenized tissue according to protocols benchmarked for the 156 
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Earth Microbiome Project (EMP) found here: http://www.earthmicrobiome.org/emp-standard-157 
protocols/ 8,9. 158 
  159 
LC-MS/MS Mass Spectrometry: A 50 μl aliquot of the extracted sample in methanol was 160 
added to a 96-well plate and diluted with 150 μl of LC-MS grade methanol containing 2 μl of ampicillin 161 
MS internal standard. The chromatographic separation was conducted on a ThermoScientific 162 
UltraMate 3000 Dionex UPLC system (Fisher Scientific, Waltham, MA USA) with eluent subsequently 163 
electrospray ionized and analyzed with a Bruker Daltonics® MaXis qTOF mass spectrometer (Bruker, 164 
Billerica, MA USA). Metabolites were separated using a Kinetex 2.6 μm C18 (30 x 2.10 mm) UPLC 165 
column containing a guard column. Mobile phases A 98:2 and B 2:98 ratio of water and acetonitrile, 166 
respectively, containing 0.1% formic acid and a linear gradient from 0 to 100% for a total run time of 167 
840 s at a flow rate of 0.5 mL min-1 were used. The mass spectrometer was calibrated daily using 168 
Tuning Mix ES-TOF (Agilent Technologies) at a 3 mL min-1 flow rate. A lock mass internal calibration 169 
was used by soaking a wick with hexakis (1H,1H,3H- tetrafluoropropoxy) phosphazene ions 170 
(Synquest Laboratories, m/z 922.0098) located within the source. Full scan MS spectra (m/z 50 – 171 
2000) were acquired in the qTOF and the top ten most intense ions in a particular scan were 172 
fragmented using collision induced dissociation at 35 eV for +1 ions and 25 eV for +2 ions in the 173 
collision cell. A data dependent automatic exclusion protocol was used such that an ion was 174 
fragmented upon its first detection, then fragmented twice more, but not again unless its intensity was 175 
2.5x the previous fragmentation. The isolation width was dependent on m/z with a 4 m/z isolation for 176 
50 m/z to 8 m/z at 1000 or higher.  This exclusion method was cyclical, being restarted after every 30 177 
seconds.  178 
Mass spectrometry data for the mice fed a high-fat diet compared to normal chow for 10 179 
weeks was generated separately from this study on a ThermoScientificTM qExactiveTM mass 180 
spectrometer according to the procedure of1. The mass spectrometry data generation for the HMP2 181 
(PRISM and iHMP datasets) was completed also on a ThermoScientificTM qExactiveTM, but in negative 182 
mode as described in10. These methods are less likely to capture known microbiome derived volatiles 183 
such as short chain fatty acids. 184 
  185 
Metabolomics Data Processing and Analysis. Each LC-MS/MS file in the Bruker format (.d) 186 
was converted to .mzXML format using the Bruker® DataAnalysis ‘Process with Method’ batch script. 187 
Lock mass calibration was applied during conversion to aid in mass accuracy. The .mzXML files were 188 
uploaded to the UCSD MassIVE data storage server for GNPS analysis. The entire dataset is publicly 189 
available and found under the ID MSV000079949. In addition, the area under curve feature 190 
abundances were calculated in batch for all files using the Optimus11 software based on the OpenMS 191 
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feature finding algorithms12. The Optimus parameters were as follows: m/z tolerance 15.0 ppm, noise 192 
threshold of 3000, retention time tolerance of 20 s, intensity factor compared to blanks at 3.0, and a 193 
feature observation rate of 0.01. The data was then trimmed to contain information only from 60 s to 194 
550 s of the run during the linear gradient; this removed wash steps programmed into the run at the 195 
start and end of the chromatographic program. The feature abundances were normalized to the total 196 
ion current (TIC) in each sample for statistical analysis by dividing the area-under-curve abundance 197 
for each feature in each sample by the total ion current of that sample (TIC-normalization). For organ-198 
by-organ beta-diversity analysis the features present in individual organs were extracted as separate 199 
feature tables and any features not present at all in a particular organ were removed. Additional data 200 
for the HFD study1 was generated with a ThermoScientificTM qExactiveTM mass spectrometer, and 201 
processed using the mzMine software13 with the feature table TIC-normalized. Parameters were as 202 
follows: MS1 minimum threshold of 10000 counts, MS2 threshold of 5000 counts, a mass tolerance of 203 
0.03Da and retention time tolerance of 0.2 min. The data was deconvoluted, deisotoped and filtered 204 
for compounds present in at least 3 samples. This additional metabolomics dataset is publicly 205 
available under MassIVE ID MSV000082480. 206 
         Molecular networking was performed on GNPS with the GF and SPF mice samples separated 207 
from each other and from blank and quality control samples using the group-mapping feature. The 208 
molecular networking and MS-cluster parameters were as follows: parent and fragment ion mass 209 
tolerance 0.05 Da, minimum cosine score of 0.7, minimum matched fragment ions of 4, and a 210 
minimum cluster size of 4 (to minimize detection of more rare nodes found in few samples). The 211 
library search parameters of the molecular networking search were a minimum-matched peaks of 4 212 
and a cosine score of 0.65. Any library hits from the results were inspected directly between the 213 
spectrum and query and are considered level two according to the metabolomics standards 214 
consortium guidelines14. The estimated false discovery rate (FDR) for spectral matching is 4.1% under 215 
our search parameters15. A link to the full data molecular network used for statistical analysis and 216 
annotation is available 217 
here https://gnps.ucsd.edu/ProteoSAFe/status.jsp?task=9ea760fb819449d7bc7aca8fec07bd8d. 218 
 Meta-mass shift chemical profiling of chemical transformations between nodes was done using 219 
the method of16. Briefly, all nodes unique to either GF or SPF were searched for an edge connection 220 
to a node from one or the other groups (GF to SPF, SPF to GF, GF to shared or SPF to shared). This 221 
represented a molecule unique in either GF or SPF mice that was related to a molecule in the other 222 
group, indicating it was modified in sterile or colonized mice. In each instance, the mass gain or loss 223 
relative to the unique node was recorded along with the spectral count for each node as a measure of 224 
its abundance. Mass differences were binned into known molecular modifications within a 0.03 Da 225 
window as described in16 with the addition of unique modifications relevant to this dataset, such as 226 
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saccharides. All other unknown mass shifts were ignored. Mass shifts that were counted included H2 227 
(m/z2.02) acetyl (m/z42.05), methyl (m/z14.02), H2O (m/z18.01), C2H4 (m/z28.03) O (m/z16.00), 228 
CH2O (m/z30.91), NH3 (m/z17.03), C2H2 (m/z26.02), C (m/z12.01), C2 (m/z24.02), CH4 (m/z16.04), 229 
SO3 (m/z79.96), C4H8 (m/z56.06), 2H2 (m/z4.03), C2H6 (m/z30.05), CH2O2 (m/z46.01), CO2 230 
(m/z43.99), OH (m/z17.01) and sugars corresponding to C6H10O4 (m/z146.06), C6H10O5 (m/z162.05), 231 
C5H8O4 (m/z132.04) and 2 glycone units C12H18O11 (m/z338.09). The spectral counts for node 232 
representing the specific modification were summed and plotted as total spectral counts for that 233 
modification in GF and SPF mice as either mass gains or losses. 234 
 235 
16S rRNA Gene Amplicon Sequencing of Mouse Samples: On all murine samples 236 
collected both GF and SPF and control samples of solutions and swabs underwent DNA extraction, 237 
16S rRNA gene variable region 4 (V4) PCR and amplicon preparation for sequencing according to 238 
protocols benchmarked for the Earth Microbiome Project (EMP) found 239 
here: http://www.earthmicrobiome.org/emp-standard-protocols/ 9,17. The microbiome data was 240 
processed through the Qiita software (qiita.ucsd.edu). The data was demultiplexed, reads trimmed to 241 
150 bp, and Deblur18 was used to de-noise the data into sub-OTUs (sOTUs). The resultant .biom files 242 
were used for downstream analysis with QIIME8. To create a phylogenetic tree for UniFrac19 analysis, 243 
deblurred sOTU sequences were inserted into the annotated Greengenes20 tree with SEPP21 and 244 
taxonomy assigned using the corresponding taxonomic label on the internal node where the 245 
sequence inserted. The microbiome data is available at (https://qiita.ucsd.edu/, study ID:10801). 246 
 247 
3D Mapping in ‘ili: Metabolomics and microbiome data were mapped onto the 3-D mouse 248 
model by recording the location of the sampling and orientation of each sample in the model 249 
according to the methods described in11. Some organs only contained one sample (bladder, blood, 250 
cervix, gall bladder and thymus) all other organs contained 2-6 samples and the actual location of the 251 
dissected sample was mapped to the appropriate point representing that same sample in the 3D 252 
model. The point mapping was done using the GeoMagic® Wrap software. The full .stl model of the 253 
laboratory mouse was loaded into GeoMagic Wrap and the location of each sampling point was 254 
selected with the ‘points’ tool (available as supplemental data). The x,y,z coordinate information in the 255 
model from all points was then exported as a .csv file for matching to its representative sample in the 256 
metabolomics or microbiome data (available as supplemental data). Sub models of different organ 257 
systems were also created in the same manner to aid visualization, such as the GI tract and liver. 258 
Mapping to these models was done as described for the full model. For ‘ili visualization, the matching 259 
samples for the 4 GF and 4 SPF mice were averaged and a new feature or OTU table created based 260 
on these mean abundances. This feature table was then matched to the x,y,z coordinates from the 261 
 8 
model according to the correct sample. This OTU or metabolite feature table was then uploaded into 262 
the ‘ili software simultaneously with the mouse model. This enabled automatic mapping of the 263 
abundance of a microbial or metabolite variable to the point representing its collection location in the 264 
GF and SPF mouse 3D-model. Visualization in ‘ili was done using a linear scale with the ‘viridis’ color 265 
map and automatic min/max mapping was selected. 266 
  267 
Statistical Analysis Of the Mouse Data: The microbiome .biom table and metabolome 268 
feature table were analyzed using principal coordinate analysis after calculation of a distance matrix 269 
between all samples. Alpha diversity of the metabolome data was calculated using the Shannon-270 
Weiner index on the TIC-normalized feature table from the murine GI tract in the R statistical software. 271 
The microbiome distance matrix was generated using the unweighted UniFrac distance22 in QIIME 272 
and QIIME2. Beta-diversity of the microbiome data was calculated on a feature table rarified to 500 273 
reads per sample to enable visualization of GF and sterile samples which had a low number of 16S 274 
rDNA gene reads.  Repetition at higher read thresholds produced very similar results for the SPF 275 
samples, as expected from prior studies. The metabolomic beta-diversity was calculated using the 276 
Bray-Curtis dissimilarity. The resulting distance matrix was visualized using principal coordinates 277 
analysis (PCoA) and each sample highlighted by either GF/SPF or organ source for both groups of 278 
mice. To assess the overall similarities between the metabolome of murine organs the Bray-Curtis 279 
dissimilarity was calculated between all paired samples (compared for the same subsection location 280 
for the same organ) between the GF and SPF states for all mice and these dissimilarities were 281 
averaged per organ and plotted with notch plots. This same comparison was done within GF and SPF 282 
groups to determine the level of variation for mice of the same classification. In addition, the within 283 
group variation was compared between GF and SPF mice separately in the same manner. 284 
         To determine the number of unique metabolites between GF and SPF in each organ molecular 285 
networks were built with the same above parameters for samples from each of the 29 organs. The 286 
molecular networking data was then downloaded from GNPS and the source of each node as GF or 287 
SPF was tabulated. A spectrum was considered unique to either class of mice only if it was detected 288 
in at least 3 out of 4 individual mice sampled per category. Each instance of these unique nodes was 289 
counted and reported as a percentage of the total number of nodes from each organ and as the total 290 
number of nodes per organ to visualize abundance. This was also done at the level of each individual 291 
mouse comparison to obtain a degree of variation in the overall unique metabolite differences. 292 
         To visualize the effect of the GF or SPF classification on the gut metabolomic data a random 293 
forests classification was run on all GI tract samples (including the esophagus) and the variable 294 
importance for classification of each metabolite was determined. The random forest analysis was 295 
done using 5000 trees with the R-statistical package ‘random forests’. The variable importance plot 296 
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was then computed for the metabolites most differentiating the GF and SPF states of the animals. 297 
These variables of importance were analyzed for known compounds in GNPS and their molecular 298 
family memberships. The 30 most differentially abundant metabolites according to their variable 299 
importance were then visualized using a stacked bar graph showing their relative abundance to the 300 
entire metabolome. This enabled visualization of the changes in the most differential metabolites 301 
through the GI tract and an indication of how abundant these differential metabolites were overall. The 302 
Shannon-Weiner index of diversity was calculated on the entire metabolome from each GI tract 303 
associated sample using the R statistical software. The mean Shannon-Weiner diversity for each 304 
sample location was visualized for the two groups of mice through the GI tract. The Mann-Whitney U-305 
test was used to determine a statistically significant difference (p< 0.05) between the Shannon 306 
diversity of each GI tract sample collected at the same location between the GF and SPF mice. The 307 
microbiome diversity was calculated using the Faith’s phylogenetic diversity index in the Qiita software 308 
and mean diversity between the four individual mice was presented only for the SPF mice. 309 
 Tests of the differential abundance of the novel bile acids between mice fed antibiotics or high 310 
fat were done using the Mann-Whitney U-test with a significance level of p<0.05. Correlations 311 
between the feature abundance of the novel bile acids and bacterial OTUs from the HFD experiment 312 
were calculated using the Pearson’s correlation on deblurred reads. Reads with the highest 313 
correlations were assigned by BLAST to the NCBI nucleotide database with only cultured 314 
representatives included in the search. 315 
 The alpha diversity of the batch culture experiment was calculated using the Shannon-Index 316 
on the deblurred OTU table produced through Qiita and the duplicate sequenced samples were 317 
averaged. 318 
 319 
Synthesis of Novel Conjugated Bile Acids. The procedure was adapted from a previous 320 
method by Ezawa et al.23 Cholic acid (100mg, 0.25mmol, 1 eq.) was dissolved in THF (4.9mL, 321 
0.05mM) and cooled to 0oC in an ice water bath with stirring. Ethyl chloroformate (28µL, 1.2 eq.) was 322 
added followed by triethylamine (41µL, 1.2eq) and the reaction stirred for 0.5 hours cold. After 323 
complete conversion of the starting material by TLC a cold, aqueous solution (4.9mL) of amino acid 324 
(0.37mmol, 1.5 eq.) and base (0.37mmol, 1.5 eq.) is added in one portion. The reaction is stirred for 1 325 
hour at 0oC to completion. THF is removed under reduced pressure and 2M HCl is added to acidify to 326 
pH < 2 and a white precipitate appears. The mixture was extracted with ethyl acetate (3 x 20mL), the 327 
combined organic layers washed with brine (1 x 50mL), dried over sodium sulfate, and concentrated. 328 
Purification was done by column chromatography with 6% --> 18% Methanol/DCM + 1% acetic acid to 329 
give the desired product as a white solid. 330 
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 331 
Leucine Conjugate: 62% Yield. Product made using the general procedure. White solid. 1H 332 
NMR (600 MHz, MeOD) δ 4.37 (s, 1H), 3.96 (s, 1H), 3.80 (d, J = 2.6 Hz, 1H), 3.40 – 3.34 (m, 1H), 333 
2.36 – 2.22 (m, 3H), 2.21 – 2.13 (m, 1H), 2.03 – 1.94 (m, 3H), 1.93 – 1.78 (m, 4H), 1.78 – 1.51 (m, 334 
10H), 1.47 – 1.27 (m, 5H), 1.15 – 1.06 (m, 1H), 1.04 (d, J = 6.5 Hz, 3H), 1.02 – 0.94 (m, 4H), 0.94 – 335 
0.89 (m, 6H), 0.71 (s, 3H). 13C NMR (151 MHz, MeOD) δ 176.80, 74.05, 72.87, 69.04, 48.12, 47.49, 336 
43.18, 42.99, 41.96, 41.00, 40.44, 36.91, 36.48, 35.90, 35.85, 34.02, 33.33, 31.16, 29.56, 28.73, 337 
27.86, 26.13, 24.24, 23.56, 23.16, 21.81, 17.73, 13.00. M.P. = 175-178C. IR – 3390.24, 2933.2, 338 
2868.59, 2426.01, 1634.38, 1464.67.  HRMS (ESI) exact mass calculated for [M+H]+ (C30H52NO6) 339 
requires m/z 522.3789, found 522.3793 with a difference of 0.77 ppm. 340 
Isoleucine Conjugate: 58% Yield. Product made using the general procedure. White solid. 1H 341 
NMR (599 MHz, MeOD) δ 4.32 – 4.27 (m, 1H), 3.96 (s, 1H), 3.80 (d, J = 2.8 Hz, 1H), 3.40 – 3.34 (m, 342 
1H), 2.38 – 2.15 (m, 4H), 2.03 – 1.93 (m, 3H), 1.93 – 1.78 (m, 4H), 1.78 – 1.50 (m, 10H), 1.45 – 1.27 343 
(m, 4H), 1.26 – 1.19 (m, 1H), 1.11 (qd, J = 11.8, 5.6 Hz, 1H), 1.05 – 1.02 (m, J = 7.0, 2.0 Hz, 3H), 344 
1.01 – 0.90 (m, 10H), 0.71 (s, 3H). 13C NMR (151 MHz, MeOD) δ 176.86, 74.06, 72.87, 69.04, 48.12, 345 
47.48, 47.48, 43.18, 42.98, 41.00, 40.44, 38.33, 36.93, 36.48, 35.89, 35.84, 33.87, 33.35, 31.16, 346 
29.56, 28.72, 27.86, 26.24, 24.23, 23.17, 17.73, 16.15, 13.00, 11.85. M.P. = 144-148C. IR – 3392.17, 347 
2933.2, 2871.49, 2483.87, 1639.20, 1461.78. HRMS (ESI) exact mass calculated for [M+H]+ 348 
(C30H52NO6) requires m/z 522.3789, found 522.3792 with a difference of 0.57 ppm. 349 
Phenylalanine Conjugate: 63% Yield. Product made using the general procedure. White 350 
solid. 1H NMR (599 MHz, MeOD) δ 7.28 – 7.17 (m, 5H), 4.60 (dd, J = 8.9, 4.8 Hz, 1H), 3.93 (t, J = 2.7 351 
Hz, 1H), 3.80 (d, J = 2.8 Hz, 1H), 3.40 – 3.35 (m, 1H), 3.22 (dd, J = 13.9, 4.8 Hz, 1H), 2.94 (dd, J = 352 
13.9, 9.1 Hz, 1H), 2.33 – 2.18 (m, 3H), 2.11 – 2.04 (m, 1H), 2.01 – 1.94 (m, 3H), 1.86 – 1.78 (m, 3H), 353 
1.76 – 1.63 (m, 3H), 1.62 – 1.50 (m, 5H), 1.47 – 1.33 (m, 3H), 1.21 (m, 2H), 1.09 (qd, J = 11.9, 5.3 Hz, 354 
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1H), 1.02 – 0.95 (m, 4H), 0.92 (s, 3H), 0.68 (s, 3H). 13C NMR (151 MHz, MeOD) δ 17138.76, 130.28, 355 
129.38, 127.68, 74.04, 72.87, 69.04, 48.02, 47.44, 43.18, 42.97, 40.99, 40.44, 38.47, 36.84, 36.48, 356 
35.89, 35.84, 33.87, 33.23, 31.16, 29.56, 28.66, 27.86, 24.22, 23.16, 17.66, 13.00. M.P. = 142-146C. 357 
IR – 3395.07, 2934.16, 2865.70, 2494.47, 1638.23, 1455.99.  HRMS (ESI) exact mass calculated for 358 
[M+H]+ (C33H50NO6) requires m/z 556.3633, found 556.3637 with a difference of 0.72 ppm. 359 
Tyrosine Conjugate: 57% Yield. Product made using the general procedure. White solid. 1H 360 
NMR (599 MHz, MeOD) δ 7.03 (d, J = 8.5 Hz, 2H), 6.68 (d, J = 8.5 Hz, 2H), 4.52 (dd, J = 8.6, 4.8 Hz, 361 
1H), 3.94 (t, J = 2.7 Hz, 1H), 3.80 (d, J = 2.8 Hz, 1H), 3.40 – 3.34 (m, 1H), 3.11 (dd, J = 14.0, 4.8 Hz, 362 
1H), 2.84 (dd, J = 13.9, 8.8 Hz, 1H), 2.33 – 2.20 (m, 3H), 2.07 (m, 1H), 2.02 – 1.93 (m, 3H), 1.88 – 363 
1.78 (m, 3H), 1.77 – 1.63 (m, 3H), 1.62 – 1.51 (m, 5H), 1.45 – 1.34 (m, 3H), 1.27 – 1.18 (m, 2H), 1.10 364 
(qd, J = 11.8, 5.4 Hz, 1H), 1.02 – 0.95 (m, 4H), 0.92 (s, 3H), 0.69 (s, 3H). 13C NMR (151 MHz, MeOD) 365 
δ 176.65, 157.21, 131.26, 129.41, 116.10, 74.05, 72.87, 69.05, 48.05, 47.44, 43.17, 42.97, 40.99, 366 
40.44, 37.73, 36.85, 36.47, 35.89, 35.83, 33.95, 33.26, 31.16, 29.55, 28.67, 27.86, 24.23, 23.16, 367 
17.67, 13.00. M.P. = 174-178C. IR – 3398.92, 2936.09, 2867.63, 1614.13, 1446.35. HRMS (ESI) 368 
exact mass calculated for [M+H]+ (C33H50NO7) requires m/z 572.3582, found 572.3584 with a 369 
difference of 0.35 ppm. 370 
13C9, 15N-labelled Tyrosine Conjugate: 94% yield. Product made using the general procedure 371 
with slight modifications.  The reaction time for initial activation of the carboxylic acid at 0°C was 372 
extended from 0.5 h to 2 h.  Additionally, following addition of the labelled tyrosine and NaOH, the 373 
reaction time was extended to 2h. The product was obtained as a white solid.  1H NMR (599 MHz, 374 
MeOD) δ 7.21 – 6.86 (m, 2H), 6.85 – 6.52 (m, 2H), 4.56 (d, J = 141.7 Hz, 1H), 3.94 (t, J = 3.0 Hz, 1H), 375 
3.80 (q, J = 3.1 Hz, 1H), 3.41 – 3.35 (m, 1H), 3.27 – 2.97 (m, 1H), 2.97 – 2.67 (m, 1H), 2.33 – 2.19 (m, 376 
3H), 2.14 – 2.04 (m, 1H), 2.03 – 1.90 (m, 3H), 1.89 – 1.77 (m, 3H), 1.77 – 1.62 (m, 3H), 1.62 – 1.48 377 
(m, 5H), 1.47 – 1.32 (m, 3H), 1.25 – 1.16 (m, 2H), 1.09 (qd, J = 11.9, 5.6 Hz, 1H), 1.03 – 0.94 (m, 4H), 378 
0.91 (s, 3H), 0.68 (s, 3H).  13C NMR (151 MHz, MeOD) δ 157.13, 157.06, 131.21 (t, J = 55.2 Hz), 379 
128.95, 116.16 (t, J = 62.4 Hz), 74.05, 72.82, 69.08, 49.43, 49.28, 49.14, 49.00, 48.86, 48.72, 48.57, 380 
48.00, 47.39, 43.06, 42.90, 40.88, 40.35, 37.56 (dd, J = 47.0, 27.7 Hz), 36.77, 36.41, 35.83, 35.75, 381 
33.84, 33.20, 31.08, 29.46, 28.60, 27.78, 24.19, 23.13, 17.66, 12.98. 382 
 383 
Novel Bile Conjugates Validation Experiments. To validate the synthetic standards of the 384 
tyrosine, phenylalanine, leucine and isoleucine cholic and muricholic acids conjugates, the 385 
compounds were dissolved in methanol, diluted to 5 μM and run on the LC-MS/MS method described 386 
above. The data is publicly available under MassIVE ID: MSV000082467. Retention times and 387 
MS/MS spectra were analyzed to verify the molecular characteristics. To determine the approximate 388 
concentration of Phe-chol in the murine GI tract an ileal sample from a GF mouse was spiked with 389 
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standard curve of concentrations of pure Phe-chol (non-murine form). Final concentrations of 100 μM, 390 
25 μM, 5 μM, 1 μM, 0.1 μM and 0.02 μM, were directly added to the extracted ileal sample and 391 
analyzed with mass spectrometry using the same methods as described above. A standard curve of 392 
these concentrations was calculated by plotting the known concentrations to their corresponding area-393 
under-curve (AUC) abundance of the Phe-chol peak. The same AUC abundance was then captured 394 
for each sample positive for the molecule in the colonized mice. The concentration in the murine 395 
samples was then calculated based on the concentrations of the standard curve. Because isoleucine 396 
and leucine cannot be distinguished with MS/MS data, we analyzed the synthetic isoleucocholic acid 397 
standard and leucocholic acid standard on an extended gradient HPLC column. The two standards 398 
were injected with the jejunum3 sample from mouse SPF2 and subjected to a 40% LC gradient of the 399 
same solvents described above with ramp to 40% solvent B at 3 minutes followed by 22 min of 400 
ramping to 100% B and then wash steps. The MS/MS method was identical to that described above 401 
and retention time differences were recorded between the two chemical standards and the murine 402 
sample. To determine whether the base bile acid was either cholic or muricholic acids, the muricholic 403 
forms were synthesized according to the supplementary methods in place of cholic acids and all 3 404 
amino acid conjugates of each bile acid backbone were analyzed using the original LC-MS/MS with 405 
sample SPF2 jejunum 3, which contained the same molecules detected in the murine gut. Retention 406 
time analysis was used to identify whether each molecule in the mouse sample was either muricholic 407 
or cholic acid forms. Links to mirror plots showing matches between the novel conjugated bile acids in 408 










Mining Public Data Mining on GNPS. The single spectrum search feature in GNPS 419 
(MASST, https://gnps.ucsd.edu/ProteoSAFe/index.jsp?params=%7B%22workflow%22:%22SEARCH420 
_SINGLE_SPECTRUM%22,%22library_on_server%22:%22d.speclibs;%22%7D) that allows one to 421 
search public MS/MS data through spectral alignment11 was used to search for the unique amino acid 422 
conjugated bile acids in publicly available data. The parameters of the search were as follows: 0.03 423 
Da window of parent mass and fragment ion matching, 0.7 cosine score and a minimum matched 424 
peaks of 4 ions. In datasets with a positive hit, the source organism and % of samples positive for 425 
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each compound was recorded. Two datasets comprised of LC-MS/MS data analyzed on a Bruker 426 
Maxis qTOF from fecal swabs of CF patients (massive IDs MSV000079134 and MSV000082406) 427 
were further analyzed according to the metadata of the studies as pancreatic sufficient, insufficient or 428 
samples from healthy individuals. The presence of an MS/MS spectrum for each of these classes was 429 
tabulated by individual and reported as the percent of subjects positive for each molecule in each 430 
class. The results from the MASST searches are available at the following links: Phe, Tyr, and Leu 431 
and can be cloned to search against all public data sets that have become available through GNPS 432 
since the these jobs were performed in Sept 2018.   433 
 434 
Development of UPLC-Triple Quadrupole Mass Spectrometry Method for Bile Acids 435 
Quantification and Assessment of Matrix Effects. The above chromatography method used in the 436 
murine tissues analysis was transferred to a Thermo Ultimate 3000 UHPLC coupled with a Thermo 437 
TSQ Quantum Access Max ESI triple quadrupole (QQQ) system. An identical column, mobile phases, 438 
sample injection volume, and column thermostat temperature setting were used as described in the 439 
LC-MS/MS section above. However, In order to increase sample throughput, the gradient was slightly 440 
modified: gradient elution was set to start with one-minute hold at 5% organic composition, then 441 
linearly increase to 90% over four minutes followed by 90% organic content hold for 2 minutes and 442 
decrease to 5% and hold for 5 minutes to equilibrate the system before the subsequent injection. The 443 
flow rate was set to 0.25 ml/min to match optimal operating regime for the QQQ mass analyzer. The 444 
ESI sprayer parameters are summarized in table S5. Multiple reaction monitoring (MRM) transitions 445 
were selected to achieve the highest sensitivity and specificity of the targeted molecules. The optimal 446 
MRM transitions were selected independently for both regular and stable 13C-Phenylalanine isotopic 447 
labeled synthetic conjugate and 13C9,15N-Tyrosine isotopic labeled synthetic conjugate. The Retention 448 
Time (RT) and two transitions per molecule were used for the specificity to achieve level 1 449 
annotation14. These MRM parameters of all quantified molecules are summarized in Table S5. 450 
 451 
Assessment of Matrix Effects and Measuring of Limit of Detection (LOD) in Different 452 
Matrices Matrix effects on the novel conjugated bile acids from the murine GI tract samples were 453 
evaluated to characterize the interferences observed during the untargeted analysis. For this, sample 454 
aliquots for each tissue and sample type of GF mice were pooled together, injected, and quantified 455 
using an external standard calibration. The calibration curve was created using standards in the 5 456 
ng/ml to 250 ng/ml range. The same samples were also spiked with the 50 ng/ml of each bile acid 457 
conjugate and analyzed in identical fashion. Matrix effect values were calculated by comparing the 458 
expected value (50 ng/ml) to the difference observed between the assayed samples and the samples 459 
with added standard (table S5). As the matrix could affect the LODs due to ion suppression or ion 460 
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enhancement; the GF samples (which do not contain the target compounds) were spiked with 461 
different concentrations and injected to the HPLC-MS system. Limit of detection was calculated as 462 
three times of the standard error of the fitted regression line divided by the slope for each conjugate 463 
separately and for each tissue type.  464 
 465 
Quantification of Novel Bile Conjugates in SPF mice with Internal Standard Calibration 466 
and Matrix Matched Calibration. The original samples from SPF mice were re-analyzed with the 467 
HPLC-ESI-QQQ targeted quantification method described above with two separate quantification 468 
approaches. 1) Internal Standard Calibration: all samples were injected with 2 µL of 13C-Phenylalanine 469 
isotopic labeled synthetic bile conjugate and 13C9,15N-Tyrosine isotopic labeled synthetic bile 470 
conjugate as internal standard mixture (250 ng/ml); mixed in the HPLC injector loop. As the Phe-chol 471 
internal standard only had one 13C modification the natural distribution contribution of the M+1 isotope 472 
was corrected during the calculation. 2) Matrix-matched calibration: calibration curves were built to 473 
cover the range of 2.5 ng/ml to 1 µg/ml for each tissue type by adding external standards into pooled 474 
GF mice samples lacking targeted bile conjugates. For both calibrations, linear fitting was used to 475 
determine slope and intercept of the calibration curve. These parameters were used to calculate the 476 
concentration of unknown samples. The obtained concentrations were then expressed in µM/g 477 
quantities based on masses of original samples. 478 
 479 
Quantification of The Phenylalanine Bile Acid Conjugate Production by Bacterial 480 
Strains. Correlations between the novel bile acids were assessed using the Pearson correlation and 481 
mmvec25. Cultures of C. bolteae CC43 001B and C. bolteae WAL-14578 strains were extracted as 482 
previously described for the mouse sample processing method. The bile acids in the extracts were 483 
quantified using targeted quantification method described above. Elution gradient was set to start with 484 
one-minute hold at 5% organic composition, then linearly increase to 90% over four minutes followed 485 
by 90% organic content hold for 2 minutes and decrease to 5% and hold for 5 minutes to equilibrate 486 
the system before the subsequent injection. The flow rate was set to 0.25 ml/min throughout. The 487 
calibration curves were calculated from a range of 0.25 ng/ml to 100 ng/ml with standards. 488 
 489 
Fecal Culture Bioreactor Inoculation. A 4g stool sample was resuspended in 40mL modified 490 
yeast casitone fatty acids media (mYCFA, DMSZ recipe) with 0.25% Antifoam B Silicon Emulsion 491 
(Baker) in a vinyl anaerobic chamber (Coy). The resuspension was centrifuged at 500 x g for 5 492 
minutes to pellet solids. The supernatant was decanted through a sterile 70 μM filter. The filtrate was 493 
centrifuged at 4450 x g for 10 minutes to pellet cells. The supernatant was discarded, and the pellet 494 
was resuspended in 40mL mYCFA. The resuspension was drawn into a 60 mL syringe and injected 495 
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into a 500 mL vessel of an Infors Multifors 2 bioreactor. The chemostat process parameters was 496 
modified from a previous process developed in26. The chemostat volume parameters were; 400 mL 497 
culture volume, 24-hour retention rate, 50 mL/min nitrogen, stirrer at 250 rpm, and 37°C temperature. 498 
10mM stocks of cholic acid, chenodeoxycholic acid, glycocholic acid, Leu-chol, Phe-chol and Tyr-chol 499 
were prepared in 100 μL methanol. 15 μL stocks were added to 12 mL mYCFA. After 11 days of 500 
continuous culturing, 24 mL bioreactor culture was withdrawn and transferred to the anaerobic 501 
chamber. 3mL culture was added to the 12mL mYCFA aliquots with the bile acids, for a total volume 502 
of 15mL and final concentration of 10 μM bile acid. The cultures were vortexed and split into three 503 
5mL aliquots. At time 0 (blanks for each bile acid), 1, 3, 6, 12 and 24 hours, 0.1mL aliquots were 504 
removed from the samples for metabolomics and 16S rRNA gene sequencing. 505 
A separate experiment in 96 deep-well plate format was completed in similar fashion with 506 
media formulated according to26 (designed to mimic human gut contents). A fresh fecal swab 507 
(sampled according to methods from the American Gut Project2) was first resuspended in 1x PBS and 508 
then 20 μL of fecal resuspension was inoculated into 500 μL of media in each well. Conjugated bile 509 
acids (Phe-chol, Tyr-Chol, Leu-Chol and Gly-chol) were added to the cultures prior to incubation in 510 
triplicate. The cultures were incubated at 37°C for 48 hours. Both culture experiments (batch culture 511 
and 96-well plate format) were extracted with 70% methanol according to the same methods 512 
described above and analyzed with LC-MS/MS using the same instrument and methods as described 513 
above for GF and SPF mouse studies. The batch culture experiment had microbiome sequencing 514 
completed and analyzed. 515 
 516 
16S rRNA Gene Amplicon Sequencing of Batch Cultures. DNA was extracted from the 517 
bioreactor samples using QIAGEN AllPrep 96 PowerFecal DNA/RNA, (QIAGEN custom product # 518 
1114341) with bead-beating on a Tissuelyser II (QIAGEN). 16S rRNA gene libraries targeting the V4 519 
region of the 16S rRNA gene were prepared by first using qPCR to normalize template concentrations 520 
and determine optimal cycle number.  To ensure minimal over-amplification, each sample was 521 
normalized to the lowest concentration sample, amplifying with this sample optimal cycle number for 522 
the library construction PCR.  Four 25 μL reactions were prepared per sample with 0.5 units of 523 
Phusion with 1X High Fidelity buffer, 200 μM of each dNTP, 0.3 μM of 515F (5’-524 
AATGATACGGCGACCACCGAGATCTACACTATGGTAATTGTGTGCCAGCMGCCGCGGTAA-3’) 525 
and unique reverse barcode primer from the Golay primer set9.  After amplification, replicates were 526 
pooled and cleaned via Agencourt AMPure XP-PCR purification system.  Prior to final pooling, purified 527 
libraries were diluted 1:100 and quantified again via qPCR (Two 25 μL reactions, 2x iQ SYBR 528 
SUPERMix (Bio-Rad, REF: 1708880 with Read 1 (5’-529 
TATGGTAATTGTGTGYCAGCMGCCGCGGTAA-3’), Read 2 (5’-530 
AGTCAGTCAGCCGGACTACNVGGGTWTCTAAT-3’). Pools were quantified by Qubit (Life 531 
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Technologies, Inc.). Final pools were sequenced on an Illumina MiSeq 300 using custom index 5’-532 
ATTAGAWACCCBDGTAGTCCGGCTGACTGACT-3’ and custom Read 1 and Read 2 primers 533 
mentioned above. 534 
 535 
Farnesoid X Receptor Stimulation from Bile Acids. Human kidney cell line HeK-293 was 536 
obtained from American Type Culture Collection (ATCC CRL-1573, tested for Mycoplasma 537 
contamination every 6 months). These cells were chosen due to their high transfectability and low 538 
FXR expression which allows for a robust signal to noise ratio. These 293 cells were cultured in 539 
Dulbecco’s modified Eagle’s medium/F-12 (DMEM) supplemented with 10% (V/V heat-inactivated 540 
fetal calf serum (FBS) and 100 units/ml penicillin G and 100 μg/ml streptomycin. 10,000 cells were 541 
seeded per well in 96-well plates one day before transfection of plasmids. DNA was transiently 542 
transfected by Lipofectamine 2000 and Opti-MDM in fasting state. The ratio of plasmid used in per 543 
well were 50ng of FXR response element (FXRE)/luciferase reporter plasmid, 10 ng of pCMV-3flag-544 
FXR (human) plasmid, 10 ng of pCMV-RXR (human) plasmid, and 5ng of Renilla luciferase reporter 545 
plasmid as internal standard for transfection efficiency. After 12 hrs of transfection, 293 cells were 546 
treated with the indicated concentration of bile acids (Phe-Chol, Tyr-Chol, Leu-Chol, CDCA, DCA and 547 
T-βMCA.) with FXR synthetic agonist GW4064 as control. Cells were harvested 24 hrs later and lysed 548 
with passive lysis buffer (Promega). Luciferase activities were measured by the Dual-Luciferase 549 
Reporter (DLR™) Assay kit and read by Luminometer (Perkin Elmer). The final Luciferase activities 550 
were normalized by dividing the relative light units by Renilla luciferase activity. Statistical analyses 551 
were performed using Prism software. Each dosage was done in 12 replicates.  552 
 553 
13C-Phenylalanine Feeding of Mice and Analysis of Fecal Samples. ApoE-/- (Jackson Labs 554 
Stock No. 002052) females approximately 16 weeks old were used for this experiment. Fecal pellets 555 
were collected from each mouse at baseline (mice were fed regular chow (RC) prior to experiment) 556 
and each day after for the duration of the experiment HFD feeding (between 9-11 am each day). Each 557 
mouse was housed in an individual cage lined with nestlets. The diet was then shifted to HFD 558 
containing 1.25% cholesterol and 21% milk fat (TD96121; Envigo, Madison, WI) at day 0. The overall 559 
experiment duration was 9 days with the final stool collection being on day 10. On days 1-3, each 560 
mouse was fed the HFD alone. On days 4-6, the experimental mouse was shifted to HFD 561 
supplemented with the 13C-labeled phenylalanine (Catalog # 490091 Sigma-Aldrich) and the control 562 
mouse to HFD supplemented with unlabeled phenylalanine. Both groups of mice were shifted back to 563 
the HFD without supplemental phenylalanine on days 7-9. The food was prepared as follows each 564 
day: each day the HFD pellets were mixed with water from the mouse bottles at 1.5mL water per 10 565 
grams of food to make a uniform slush inside a small dish that is placed on the cage bottom. For days 566 
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4-6, the amino acid powder at 10 µg/mg was spread on top of the food, water was added and mixed. 567 
Fecal samples were collected from these animals and screened for the production of labeled and 568 
unlabeled Phe-chol. Fecal samples from the feeding experiment were extracted and prepared with the 569 
same protocol as described above for the original GF and SPF mice. Targeted analysis method was 570 
used for detection of phenylalanine conjugates for both unlabeled and C13 labeled molecules. The 571 
areas under the curves were extracted and used for ratio calculations. 572 
 573 
 LC-MS Metabolomics Data Processing from PRISM and iHMP cohorts from the HMP2 574 
IBD Datasets. The raw LC-MS data were acquired to the data acquisition computer interfaced to 575 
each LC-MS system and then stored on a robust and redundant file storage system (Isilon Systems) 576 
accessed via the internal network at the Broad Institute. Nontargeted data were processed using 577 
Progenesis QIsoftware (v 2.0, Nonlinear Dynamics) to detect and de-isotope peaks, perform 578 
chromatographic retention time alignment, and integrate peak areas. Peaks of unknown ID were 579 
tracked by method, m/z and retention time. The novel conjugated bile acids were searched for by 580 
matching m/z in negative mode and subsequently verified using LC-MS/MS and synthetic standards 581 
of Phe-chol, Tyr-chol and Leu-chol from pooled samples (table S8). 582 
 583 
Statistical Analysis of HMP2 Metabolomics Data. Prior to model fitting, raw metabolite 584 
abundances were median-normalized within sample and then log-transformed with a pseudocount of 585 
1. We used linear models implemented in R to associate metabolite abundances with IBD phenotype 586 
while controlling for clinical covariates. For the cross-sectional PRISM data, we treated categorical 587 
IBD diagnosis (UC, CD, and non-IBD control) as the phenotype of interest with “non-IBD” as a 588 
reference group. Age was included as a continuous covariate, while antibiotics, immunosuppressants, 589 
mesalamine, and steroids use were coded as binary covariates. The model was evaluated as follows 590 
using R’s lm function: 591 
 592 
metabolite ~ (intercept) + diagnosis  593 
+ age + antibiotic + immunosuppressant + mesalamine + steroids. 594 
 595 
The nominal p-values of the diagnosis coefficients for each metabolite were adjusted for multiple 596 
hypothesis testing using the Benjamini-Hochberg FDR method. A more sophisticated mixed-effects 597 
model was applied per-feature to the HMP2 metabolomics data to account for repeated measures 598 
over subjects and the multiple recruitment sites within the study. In addition, the transformed 599 
abundance of each metabolite was modeled as a function of a combined phenotype: diagnosis (as 600 
defined above) and dysbiosis state as a nested binary variable within each diagnosis (with non-601 
dysbiotic as reference). The definition of “dysbiosis state” is presented in detail in the next section. 602 
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Model results were further adjusted for consent age as a continuous covariate and antibiotics use as a 603 
binary covariate. The mixed effects model was evaluated as follows using the lme function in R’s nlme 604 
package [where (1 | subject) and (1 | recruitment site) indicate random effects for subject and 605 
recruitment site, respectively]: 606 
 607 
metabolite ~ (intercept) + diagnosis + diagnosis/dysbiosis + antibiotic use + consent age + (1 | 608 
recruitment site) + (1 | subject) 609 
 610 
Statistical significance (p-value) of metabolite-phenotype associations were assessed using Wald’s 611 
test and corrected for multiple hypothesis testing as described above. 612 
Dysbiosis analyses 613 
Dysbiosis score 614 
To identify samples with highly divergent (dysbiotic) metagenomic microbial compositions in the 615 
HMP2 dataset, a “dysbiosis score” was defined as in10 based on Bray-Curtis dissimilarities to non-IBD 616 
metagenomes. First, a “reference set” of samples was constructed from non-IBD subjects by taking all 617 
samples after the 20th week after the subject’s first stool sample. This was chosen since a subset of 618 
the non-IBD subjects at the start of their respective time series may not yet have overcome any 619 
gastrointestinal symptoms that triggered the initial visit to a doctor, though ultimately not caused by 620 
IBD. The dysbiosis score of a given sample was then defined as the median Bray-Curtis dissimilarity 621 
to this reference sample set, excluding samples that came from the same subject. To identify highly 622 
divergent samples, we then thresholded the dysbiosis score at the 90th percentile of this score for 623 
non-IBD samples. This therefore identifies samples with a feature configuration that has a <10% 624 
probability of occurring in a non-IBD subject. By this measure, 272 metagenomes were classified as 625 
dysbiotic. Samples from CD and UC subjects are overrepresented in the dysbiotic set, with 24.3% and 626 
11.6% of their samples classified as dysbiotic, respectively. A metabolite measurement was then 627 
defined as dysbiotic only if its paired metagenome is defined as dysbiotic according to the above 628 
definition. Only metabolomes with matched metagenomes were used in differential abundance testing 629 
(for UC, 12 dysbiotic and 110 non-dysbiotic metabolomes; for CD, 48 dysbiotic and 169 non-630 
dysbiotic). 631 
 632 
Bile acid Gavage of Mice. Eight-week-old Male C57BL/6J mice (Jackson Laboratory) were 633 
acclimated for 14 days and housed in groups of two throughout the duration of the experiment to 634 
mitigate cage effects. Mice were then dosed 2 times (24 hour) or 4 times (72 hour) (t = 0 hr, t = 24 hr, 635 
t = 48hr, t = 72hr) by oral gavage with either a mock control of corn oil without bile acids, or corn oil 636 
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infused Tyr-chol (500 mg/kg body weight), Leu-chol (500 mg/kg body weight), cholic acid (500 mg/kg 637 
body weight) or the control FXR agonist GW4064 (10 mg/kg body weight). Starting 3 hours after the 638 
last gavage (t = 75 hr, 72 hour treatment or t = 25, 24 hour treatment), mice were euthanized by CO2 639 
asphyxiation and samples were collected within a 6 hour period and snap frozen in a liquid nitrogen 640 
bath and stored at -80°C prior to analysis. All mice were handled in accordance with guidelines for the 641 
humane care and use of experimental animals, and the procedures used were approved by the 642 
University of California, San Diego Institutional Animal Care and Use Committee and the Salk Institute 643 
for Biological Studies Institutional Animal Care and Use Committee. Ileum and liver samples were 644 
used for qPCR.  645 
 646 
RT-qPCR Analysis of Downstream FXR Gene Expression. Mouse liver and ileum segments were 647 
directly homogenized in TRIzol and total RNA isolated. cDNA was synthesized from 1μg of DNase-648 
treated total RNA using Bio-Rad iScript Reverse Transcription supermix (#1708841) and mRNA levels 649 
of Fgf15, Shp, Cyp7b1 and Cyp7a1 were quantified by quantitative PCR with Advanced Universal 650 
SyBr Green Supermix (Bio-Rad, cat #725271). All samples were run in technical triplicates and 651 
relative mRNA levels were calculated by using the standard curve methodology and normalized to 652 
36B4. All primers are listed in the Supplementary Table S9. 653 
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Supplementary Data 715 
Overall Microbiome and Metabolome Relationships. A broad overview of data relationships 716 
was first assessed through principal coordinates analysis (PCoA) using the Bray-Curtis dissimilarity 717 
matrix (metabolome) and UniFrac distance (microbiome) (Extended Data Fig. 1a). The metabolome 718 
data was most strongly influenced by organ source (Extended Data Fig. 1b,c). When plotted by organ, 719 
four distinct metabolome clusters emerged: the gastrointestinal (GI) tract, epidermal swabs, blood rich 720 
organs (lung, heart, spleen, and blood itself), and a cluster of all other visceral organs (Extended Data 721 
Fig. 1a,b). We further collected 16S inventories to understand the spatial pattern of bacterial 722 
colonization in the mice. As expected, the microbiome data was dictated by colonization status. GF 723 
mice and sterile organs in SPF mice clustered tightly with background sequence reads from blanks 724 
(reflecting their sterility), whereas colonized organs within the SPF mice clustered apart from these 725 
samples (Extended Data Fig. 1a,b). Notable separation of certain organ systems was observed in the 726 
microbiome of SPF mice, including a distinct grouping of the GI tract (including the esophagus) and 727 
clustering of the vagina and cervix samples (Extended Data Fig. 1a,b). To quantify the effect of 728 
microbial colonization on the metabolomic data, the Bray-Curtis dissimilarity was calculated between 729 
the MS1 data of GF and SPF mice, then compared to the within group variation for all paired sample 730 
locations with statistical significance being determined by Mann-Whitney U-test. The strongest 731 
separation between the metabolomic data was present in stool, followed by the cecum, other regions 732 
of the GI tract, and samples from the surface of the animals including ears and feet (Extended Data 733 
Fig. 1c). Thus, the major molecular signatures distinguishing colonized and GF mice were present in 734 
the gut and epidermis with particularly strong effects in the stool, cecum and ileum. The liver also had 735 
signatures suggestive of metabolomic differences between the GF and SPF mice, but this was not 736 
significant compared to the within individual variation (Extended Data Fig. 1c). 737 
The 16S rRNA gene microbiome profiles of the GI tract were dominated by Bacteroidales 738 
clade S24-7, Firmicutes, Lactobacillus and Akkermansia muciniphila (Extended Data Fig. 1d). Large 739 
changes in microbial profiles were observed traversing the GI tract. The esophagus, stomach and 740 
duodenum had relatively similar profiles, but a dramatic shift in the jejunum with the expansion of 741 
Lactobacillus and A. muciniphila and a decrease in the relative abundance of Bacteroidales S24-7 742 
was evident. The community transitioned again through the ileum with a further expansion of 743 
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Lactobacillus. At the cecum an abrupt transition was observed with a reduction of Lactobacillus and 744 
increase in the relative abundance of Firmicutes (Extended Data Fig. 1d), this community was largely 745 
maintained through the colon until the stool, where the Firmicutes were reduced (Extended Data Fig. 746 
1d).  747 
Unique molecules from the microbiome. Molecular networking paired with statistical analysis 748 
enabled identification of molecules unique or enriched between the two groups of mice. These 749 
included bile acids, flavonoids, triterpenoid saponins, and urobilins (Extended Data Fig. 1-4). The 750 
soyasaponins and flavonoids were prevalent, diverse and differentially abundant between the two 751 
groups of mice. These compounds were sourced from the mouse chow that had a dominant soybean 752 
component. A cluster of 76 connected nodes in the molecular network representing soyasaponins 753 
was found in both GF and SPF mice and their food pellets, but these clusters were enriched in nodes 754 
from the GI tract of GF mice (Extended Data Fig. 2). This molecular family contained a variety of 755 
unique soyasaponins all comprised of the core soyasapogenol triterpenoid backbone, but with 756 
different glycosylations and hydroxylations. Soyasaponins were present throughout the GI tract of GF 757 
mice, including the stool sample, but in SPF mice they disappeared upon passage into the cecum 758 
(Extended Data Fig. 2). Conversely, there was a separate cluster only found in SPF mice that was 759 
annotated as soyasapogenols, which represent the triterpenoid backbone of soyasaponin without 760 
glycosylation (Extended Data Fig. 2). 3D-molecular cartography showed that soyasaponin I was 761 
abundant throughout the GI tract of GF mice, particularly the cecum, colon and stool, but was absent 762 
from these organs in SPF animals. In direct contrast, soyasapogenol was not found at all in GF 763 
animals, but was detected in the cecum of the SPF mice through to the stool. This differing presence 764 
of the glycone and aglycone forms indicates that cecal microbial activity was responsible for the 765 
metabolism of soyasaponin into soyasapogenol by removal of the saccharides (Extended Data Fig. 766 
2). The abundance of soyasapogenol E (m/z 457.36) was then regressed against the microbiome 767 
data for significant associations between this metabolite and microbial operational taxonomic units 768 
(OTUs) (Bonferonni corrected p-value for 195 OTUs p < 2.6 x10-4). The Firmicute Allobaculum sp. 769 
(Pearson’s r = 0.491) was significantly correlated to the abundance of soyasapogenol E; the only 770 
cultured representative of this genus contains the β-glucosidase enzyme known to perform 771 
deglycosylation of plant natural products.  772 
Microbiome breakdown of plant flavonoids was also observed (Extended Data Fig. 3). In the 773 
mouse chow, glucuronides and aglycone flavones and isoflavones were detected, but not their 774 
sulfated forms. Because many isomeric forms of flavonoids exist that cannot be differentiated with our 775 
MS/MS methods, we focused on molecular changes in the predominant soybean isoflavonoids 776 
daidzein, genistein and glycitein, because they have characteristic MS/MS signatures. In the GF mice, 777 
3D-molecular cartography showed that the glucuronidated and sulfated isoflavonoids were detected 778 
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throughout the GI tract from the stomach through to the stool, indicating they pass through the GI tract 779 
intact. In SPF mice, however, these same glucuronides and sulfides were undetectable in the distal GI 780 
tract. The aglycones were present in both the GF and SPF mice, but more abundant in the distal GI 781 
tract of GF animals (Extended Data Fig. 3, Mann-Whitney U-test, p<0.05). Because the aglycones 782 
were detected in both groups, host and microbial enzymes (or chemical processes) could have been 783 
responsible for the deglycosylation; however, the complete removal of the sugars and sulfates in the 784 
SPF mice indicated that the microbiota significantly enhanced this process. Furthermore, in the cecum 785 
of the SPF mice, the aglycone isoflavonoids were depleted and in some cases no longer detectable 786 
through to the stool samples, indicating that further metabolism of these compounds was occurring in 787 
the cecum and colon due to the presence of bacteria.  788 
The production of secondary bile acids was also prevalent in SPF mice, but not GF mice. 789 
Deoxy- and keto-forms (dehydrogenated) of cholic acid were abundant in the distal GI tract of SPF 790 
mice but absent from GF mice (Extended Data Fig. 4). In contrast, the primary bile acid 791 
tauromuricholic acid was abundant throughout the gut of GF mice but was depleted in the distal GI 792 
tract of SPF mice. Muricholic acid was also exclusive to the guts of SPF mice but was found in the 793 
liver of sterile animals (Extended Data Fig. 4).  794 
 795 
MS/MS Annotation of Novel Conjugated Bile Acids. Analysis of the unique nodes in SPF mice 796 
related to glycocholic acid (Fig. 2a) led to the discovery of the unique conjugation with different amino 797 
acids. The major core fragment of cholic acid in all conjugated bile acids is shown in Extended Data 798 
Figure 5d at mass m/z 337.25. This represents the core steroid backbone of cholic acid with loss of 799 
the amino acid conjugate and all hydroxyl groups. In the new Tyr, Phe and Leu conjugates the 800 
difference in mass of a whole amino acid can be seen from the parent ion and this fragment. 801 
Furthermore, this amino acid ion appears in the lower m/z range of the spectrum as the whole amino 802 
acid plus a hydrogen ion (H+). Further verification of these molecules comes from the presence of 803 
unique immonium ions, a characteristic of peptide fragmentation, which are seen in the lower mass 804 
range corresponding to each of the three amino acids (Extended Data Figure 5d, table S2). 805 
 806 
Amino Acid Conjugate Synthesis and Validation. Both cholic and muricholic forms of the three 807 
novel amino acid conjugates and an isoleucine conjugate were chemically synthesized and verified 808 
using nuclear magnetic resonance spectroscopy (NMR spectra below). Polarity and MS/MS 809 
fragmentation patters of these compounds were subsequently analyzed and the higher hydrophilicity 810 
of muricholic acid forms were validated by earlier retention times for all four synthesized compounds 811 
(Extended data Fig. 5b,c). MS/MS patters of muricholic and cholic acid forms were identical and the 812 
spectra from the SPF mouse duodenum were subsequently verified to match these synthetic 813 
compounds by molecular networking, retention time analysis and MS/MS matching (Extended data 814 
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Fig. 5). In the mouse jejunum sample the extracted ion chromatogram for leucocholic acid (m/z 815 
522.3700) contained a single peak that most closely matched leucocholic acid, however, there was a 816 
small shoulder on this peak indicating that it cannot be ruled out that some isoleucocholic acid may be 817 
present (Extended data Fig. 5c). MS/MS patters of synthetic standards and novel bile acids from 818 
mouse gut samples showed high similarity (Extended data Fig. 6a) 819 
 820 
Bile Acids in Murine Portal and Peripheral Blood. An additional 4 SPF and 6 GF female mice of 821 
the same strain analyzed for the initial study on the microbial metabolome were raised for analysis of 822 
blood. Portal blood and peripheral blood were sampled as described in the methods section and 823 
analyzed with the same LC-MS/MS protocols as the original animals. Parent masses for the Phe, Tyr 824 
and Leu conjugated microbial bile acids that were searched for in the GNPS molecular network were 825 
not found (Extended data Fig. 6c). The conjugated bile acid molecular family was further inspected for 826 
the presence of these compounds but was also negative for the presence of the novel conjugates in 827 
either peripheral or portal blood samples from either mouse group. The host conjugated taurocholic 828 
acid and glycocholic acid were however, found in both blood types of both murine groups. 829 
 830 
Synthesis of Novel Conjugate Bile Acids by Clostridium bolteae. After finding a strong 831 
association between all three novel conjugates and a Clostridium sp. in mice fed high fat diet25 832 
(Extended data Fig. 7, table S3), twenty isolates of human gut bacteria were cultured in fecal culture 833 
media and screened for the production of these compounds using the same extraction and LC-834 
MS/MS methods described for the mouse organ analyses. Using GNPS integrated with mzMine 835 
feature finding, Phe-chol was detected in the extracts from three separate Clostridium strains, but at 836 
very low intensity. Only C. bolteae had produced the molecule clearly at a level at least 3x the 837 
abundance of the background extracted ion chromatogram trace. Thus, using the more sensitive 838 
targeted and quantitative assay we subsequently repeated these experiments with two isolates of C. 839 
bolteae and validated the production of both Phe-chol and Tyr-chol in the culture extracts (Extended 840 
data Fig. 8). More of the tyrosine conjugate was made than (~20 ng/ml) the phenylalanine conjugate 841 
(~7 ng/ml). Further validation was provided using media supplemented with 13C labeled phenylalanine 842 
added to the media. This labeled amino acid was incorporated into the Phe-chol produced by C. 843 
bolteae WAL-14578 demonstrating that free amino acids from the media can be used for the 844 
conjugation and providing direct evidence that these bile acids are made by microbes (Fig. 3, 845 
Extended data Fig. 8). 846 
 847 
Detection of Novel Bile Acid Conjugates in HMP2 dataset. Phe-chol, Leu-chol and Tyr-chol were 848 
detected in the HMP2 dataset with negative ion mode (table S8). The statistical testing for differences 849 
between inflammatory bowel disease patients in HMP2 are as follows: IBD patients (Fig. 3c, PRISM 850 
 25 
dataset, FDR-corrected p-value (q-value) from Wald’s test of linear effects model of Leu = 0.03, Tyr = 851 
0.0074 and Phe = 0.004, control non-IBD n = 34, CD n = 68, and UC n = 53). Furthermore, they were 852 
enriched in CD dysbiosis (HMP2 dataset q-value, Phe = 0.0003, Tyr = 0.007, Leu = 9.0 x 10-5, n=48 853 
CD-dysbiotic, n= 169 CD non-dysbiotic) but not statistically different in UC dysbiosis (q=1.0, 0.8, 0.9 854 
for Phe, Tyr, Leu-cholate amidates, n=12 UC dysbiotic, n=110 UC -non-dysbiotic) and not in non-IBD 855 
(q=0.4, 0.5, 0.5 for Phe, Tyr, Leu-cholate amidates, n=15 non-IBD-dysbiotic, n=107 non-IBD-non-856 
dysbiotic, Wald’s test). 857 
 858 
Sequencing of Fecal Cultures Exposed to Novel Bile Acid Conjugates. In the batch culture 859 
experiment where an actively growing fecal culture was exposed to the novel conjugated bile acids 860 
and other control molecules, the microbiome of the culture media was sequenced using 16S rRNA 861 
amplicon sequencing after 24 hours. The data was processed with the Qiita pipeline and the resultant 862 
cultures were analyzed for changes in the microbiome structure due to conjugated bile acid exposure. 863 
There was no change in the microbiome alpha-diversity when cultured in the presence of any bile 864 
acids added to the media compared to the mock control. The Shannon diversity of the community 865 
decreased over time, but this was not different than the mock control with no bile acids added 866 
(Extended data Fig. 8c). 867 
 868 
Quantification of Bile Acids. The concentration of the new bile acids in the mouse gut samples was 869 
quantified in negative-mode using the targeted method by comparison to the standard curves 870 
measured of each molecule in the various tissue samples spiked into the GF mice samples. The 871 
calculation was then normalized to the initial g/tissue collected (masses of samples in table S1) and 872 
the dilution through extraction and mass spectrometry analysis (Table S4, Extended data Fig. 8).  873 
 874 
Matrix Effects on Novel Conjugated Bile Acids. Standards of the novel conjugated bile acids were 875 
added to the gut and other samples of germ-free mice to determine the matrix effects on each 876 
compound in the targeted method using a triple-quad mass spectrometer (see methods). Although 877 
some ion suppression (64% for the phenylalanine conjugated cholic acid in the duodenum) and ion 878 
enhancement (135% for the leucine conjugated cholic acid in the duodenum) were observed, the 879 
average matrix effects using the positive mode method was 100% (table S6). Calculated matrix effect 880 
values were in the range of 80 to 120%, indicating low matrix effects in the ESI positive ion source on 881 
these bile acid compounds. Matrix effect was stronger using the negative-mode targeted method, 882 
particularly in the blood samples (table S7) but the limit of detection was 11x lower than positive mode 883 
thus it was used for quantification with matrix matched calibration.  884 
 885 
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RT-qPCR analysis of downstream FXR effector genes. The gene expression of Fgf15 and Shp in 886 
the ileum and Shp, Cyp8b1 and Cyp7a1 in the liver of mice gavaged with bile acids of interest were 887 
analyzed using quantitative reverse transcriptase-PCR analysis. The expression levels were 888 
normalized to the cellular housekeeping gene ribosomal phosphoprotein PO (36B4). Mice were 889 
sacrificed at both 24 hr (Extended data Fig. 9) and 72 hr post (Fig 3.e) gavage. At the 24-hr time point 890 
expression of the downstream FXR effectors Fgf15 were both significantly elevated (p<0.05) after 891 
gavage with Tyr-chol in the ileum, significance was also reached for Shp with cholic acid (CA) and the 892 
GW4064 synthetic agonist. In the liver at 24hrs, Cyp8b1 and Cyp7a1 were significantly reduced in 893 
expression in the Tyr-chol, Leu-chol and cholic acid treatments (Extended data Fig. 9). Shp signaling 894 
was not significantly affected at this time point. At 72 hrs post gavage, ileum Fgf15 and Shp signaling 895 
were significantly increased for the Tyr-chol, Leu-chol, and CA groups (Fig. 3e). Liver expression of 896 
Shp was also significantly elevated, but only in the Tyr and Leu conjugates. The bile acid synthesis 897 
enzymes Cyp8b1 and Cyp7a1 were both significantly reduced compared to the corn oil control in Tyr-898 
chol, Leu-chol and CA gavages (Fig. 3e). 899 
 900 
Supplementary Tables 901 
Table S1. Sample information from GF and SPF mice analyzed in this study. 902 
 903 
Table S2. Mass spectrometry details and ions of interest for identification of novel conjugated bile 904 
acids. 905 











acid 555.3559 556.362 H+ 120.0816 166.0862 
337.2525, 319.2420, 
227.1398 
Tyrosocholic acid 571.3509 572.356 H+ 136.0758 182.081 337.2525, 319.2420, 227.1398 
Leucocholic acid 521.3716 522.379 H+ 86.0977 132.1002 337.2525, 319.2420, 227.1398 
 906 
Table S3. Deblurred read, taxonomic assignment and Pearson’s r correlation for bacterial assigned 907 
sequence variants (ASVs) with the three novel conjugated bile acids in the HFD feeding experiment 908 
(n=12). 909 
 910 
Table S4. a) Quantification of novel conjugated bile acids in mouse SPF gut samples (n=4) and 911 
standard deviation of the mean across the different organ samples. b) Number of samples that had 912 
values above LOD included in the calculations for Table S4a. c) Limit of detection of novel conjugated 913 




Mean nmol/g tissue Standard Deviation 
Organ Tyr Phe Tyr Phe 
Jejunum 114.09 147 79.01 99.91 
Ileum 56.03 83.56 57.85 81.33 
Cecum <LOD 4.74 0 3.38 
Colon <LOD 11.61 0 12.21 
 916 
b) 917 
  Tyr Leu Phe 
Cecum 
(n=24) 0 0 11 
Colon (n=24) 0 0 9 
Ileum (n=24) 18 16 18 
Jejunum 




Limit of Detection (ppb) 
Organ Tyr Ile Phe 
Jejunum 2.70 3.12 1.74 
Ileum 2.73 1.89 3.01 
Cecum 3.30 2.45 1.78 
Colon 7.25 5.00 1.19 
 920 
Table S5. MRM transitions and mass spectrometry details for targeted method. a) Negative mode b) 921 
positive mode. Other details of the mass spectrometry method are also provided 922 
a) 923 
Negative Mode 
      Q1 Q3 CE Tube lens tr (min) 
Leu 520.4 130.2 44 100 6.31 
Leu 520.4 458.2 38 100 6.31 
Phe 554.4 147.2 42 100 6.38 
Phe 554.4 164.1 42 100 6.38 
PheC13 555.4 148.2 44 100 6.38 
PheC13 555.4 165 42 100 6.38 
Tyr 570.4 119.1 48 100 5.96 
Tyr 570.4 179.9 38 100 5.96 
Tyr10 580.4 190 41 150 5.96 
Tyr10 580.4 535.2 38 150 5.96 
 28 
Spray voltage 2500 
Vaporizer Temperature 267 
Sheath gas pressure 39 
Aux gas pressure 33 




      Q1 Q3 CE Tube lens   
Leu 522.4 337 25 170 9.36 
Leu 522.4 468.1 19 170 9.36 
Phe 556.4 337.1 23 190 9.6 
Phe 556.4 389 37 190 9.6 
Tyr 572.4 337.1 20 160 8.5 
Tyr 572.4 518 17 160 8.5 
Spray voltage 3000 
Vaporizer Temperature 350 
Sheath gas pressure 39 
Aux gas pressure 33 
Capillary temperature 380 
 926 
Table S6. Matrix effect values for different sample types in positive ionization mode for the conjugated 927 
bile acids. The effects are expressed as a percentage from the analyzed chemical standard. 928 
  Tyr-Chol Leu-Chol Phe-Chol 
Stool 124 92 95 
Jejunum 99 135 69 
Ileum 83 130 87 
Duodenum 124 128 85 
Cecum 96 91 64 
Colon 123 113 95 
Stomach 83 96 80 
 929 
Table S7. Matrix effect values for different sample types in negative ionization mode using the 930 
targeted method for the conjugated bile acids. The effects are expressed as a percentage from the 931 
analyzed chemical standard. 932 
  Tyr-Chol Leu-Chol Phe-Chol 
Ileum 27 52 48 
Cecum 66 79 77 
Colon 21 23 22 
 29 
Jejunum 32 57 55 
Fecal 67 83 86 
Blood 4 22 25 
 933 
Table S8 - Mass spectrometry and retention time characteristics of the Phe, Tyr and Leu conjugated 934 

































acid 555.3559 554.3491 5.9 min H- NA 164.0709 
302.2722,221.26
77 
tyrosocholic acid 571.3509 570.3499 5.3 min H- NA 180.066 302.2722,220.9721 
leucocholic acid 521.3716 520.3646 5.8 min H- NA 130.0864 302.2722,221.0867 
 936 
Table S9 – Primers used for qPCR quantification of Fgf15, Shp, Cyp8b-1 and Cyp7a-1 compared to 937 
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 30 
Supplemental Data: NMR Spectra. NMR spectral characterization of synthesized Leu-chol, 941 
Isoleu-chol, Phe-chol and Tyr-chol. 942 
 943 




13C NMR, 151MHz, MeOD 
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13C NMR, 151MHz, MeOD 
1H NMR, 600MHz, MeOD 
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  952 
13C NMR, 151MHz, MeOD 
 35 
Supplementary 3D Mouse Model 953 
Provided in the SI are .stl files that comprise the 3D mouse model for 3D-molecular cartography 954 
mapping. These include a full mouse model, the liver only, the GI tract only, and the GI tract without 955 
the liver. Also included are x,y,z coordinates that will enable mapping of multi-omics data to locations 956 
of interest on all four .stl files.  957 
 958 
